NCT07863180|RecruitingPhase 1/2DMCFDA Drug
Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial
BUTTER2
Tributyrin for PSP: Phase 1b Virtual Trial - Feasibility Study
Loading search results
Sponsor study identifier
interventional
15
1 country
1
Study Start
September 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
May 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
May 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
This research is studying a supplement called tributyrin in people with Progressive Supranuclear Palsy (PSP) to learn about its safety and tolerability as a potential treatment. The goal of this research study is to see if a similar supplementation regimen and virtual testing is feasible for people with PSP.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
May 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
October 1, 2026
Actual (reported)October 7, 2026
Actual (reported)May 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
May 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Tolerability of tributyrin
Tolerability will be defined as the percent of patients that dropped out of the study. (# enrolled at baseline-# enrolled on visit 7)/# enrolled at baseline
Visit 7 (approximately day 90)
Safety of tributyrin
Safety will be defined as the percent of patients who experienced serious adverse events.
Up to visit 7 (approximately day 90)
Participants will take 500mg three times a day (TID) tributyrin supplement for 90 days +/- 7 days.
Participants will take 500mg placebo for 90 days +/- 7 days.
Post-biotic short chain fatty acid dietary supplement. Participants will take 500mg TID tributyrin supplement for 90 days +/- 7 days.
Participants will take 500mg TID placebo for 90 days +/- 7 days.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Domino's Farms
Ann Arbor, Michigan, 48105, United States
Prabesh Kanel, PhD
University of Michigan
First Submitted
October 1, 2026
First Posted
October 7, 2026
Study Start
September 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
Effect of Tributyrin Supplementation on Glycemic Control, Inflammation, and Cardiovascular Risk in Patients With Type 2 Diabetes
Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy
Contact the study team to confirm eligibility.
May 2027
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
May 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
October 7, 2026
Record last verified: 2026-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: